Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

Journal of Experimental Medicine

Volumn 214, Issue 9, 2017, Pages 2573-2590

  Medina Ramírez, Max ^a   Garces, Fernando ^b   Escolano, Amelia ^d   Skog, Patrick ^c   de Taeye, Steven W ^a   Del Moral Sanchez, Ivan ^a   McGuire, Andrew T ^e   Yasmeen, Anila ^f   Behrens, Anna Janina ^g   Ozorowski, Gabriel ^b   van den Kerkhof, Tom L G M ^a   Freund, Natalia T ^d   Dosenovic, Pia ^b   Hua, Yuanzi ^b   Gitlin, Alexander D ^d   Cupo, Albert ^f   van der Woude, Patricia ^a   Golabek, Michael ^f   Sliepen, Kwinten ^a   Blane, Tanya ^c   Kootstra, Neeltje ^a   van Breemen, Mariëlle J ^a   Pritchard, Laura K ^g   Stanfield, Robyn L ^b   Crispin, Max ^g   Ward, Andrew B ^b   Stamatatos, Leonidas ^e   Klasse, Per Johan ^f   Moore, John P ^f   Nemazee, David ^c   Nussenzweig, Michel C ^d   Wilson, Ian A ^b   Sanders, Rogier W ^a,f   more..

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b IAVI Neutralizing Antibody Center and Collaboration for AIDS Vaccine Discovery (CAVD)   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; GLYCOPROTEIN GP 160;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; VIRUS ENVELOPE; ANIMAL; GENE TARGETING; HEK293 CELL LINE; IMMUNOLOGY; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CRYSTALLOGRAPHY, X-RAY; GENE KNOCK-IN TECHNIQUES; HEK293 CELLS; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MICE; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY;

EID: 85028886518     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20161160     Document Type: Article

References (94)

1. Adams, P.D., P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, et al. 2010. PHE NIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66:213-221. http://dx.doi.org/10.1107/S0907444909052925
2. Andrabi, R., J.E. Voss, C.H. Liang, B. Briney, L.E. McCoy, C.Y. Wu, C.H. Wong, P. Poignard, and D.R. Burton. 2015. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity. 43:959-973. http://dx.doi.org/10.1016/j.immuni.2015.10.014
3. Aussedat, B., Y. Vohra, P.K. Park, A. Fernández-Tejada, S.M. Alam, S.M. Dennison, F.H. Jaeger, K. Anasti, S. Stewart, J.H. Blinn, et al. 2013. Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines. J. Am. Chem. Soc. 135:13113-13120. http://dx.doi.org/10.1021/ja405990z
4. Barouch, D.H., J.B. Whitney, B. Moldt, F. Klein, T.Y. Oliveira, J. Liu, K.E. Stephenson, H.W. Chang, K. Shekhar, S. Gupta, et al. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 503:224-228.
5. Behrens, A.J., S. Vasiljevic, L.K. Pritchard, D.J. Harvey, R.S. Andev, S.A. Krumm, W.B. Struwe, A. Cupo, A. Kumar, N. Zitzmann, et al. 2016. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Reports. 14:2695-2706. http://dx.doi.org/10.1016/j.celrep.2016.02.058
6. Bonsignori, M., K.K. Hwang, X. Chen, C.Y. Tsao, L. Morris, E. Gray, D.J. Marshall, J.A. Crump, S.H. Kapiga, N.E. Sam, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitopespecific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009. http://dx.doi.org/10.1128/JVI.05045-11
7. Bonsignori, M., H.X. Liao, F. Gao, W.B. Williams, S.M. Alam, D.C. Montefiori, and B.F. Haynes. 2017. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol. Rev. 275:145-160. http://dx.doi.org/10.1111/imr.12509
8. Burton, D.R., and J.R. Mascola. 2015. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16:571-576. http://dx.doi.org/10.1038/ni.3158
9. Chen, L., Y.D. Kwon, T. Zhou, X. Wu, S. O'Dell, L. Cavacini, A.J. Hessell, M. Pancera, M. Tang, L. Xu, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 326:1123-1127. http://dx.doi.org/10.1126/science.1175868
10. Chen, V.B., W.B. Arendall III, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, and D.C. Richardson. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66:12-21. http://dx.doi.org/10.1107/S0907444909042073
11. Crespillo, S., S. Casares, P.L. Mateo, and F. Conejero-Lara. 2014. Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity. J. Biol. Chem. 289:594-599. http://dx.doi.org/10.1074/jbc.C113.524439
12. Derking, R., G. Ozorowski, K. Sliepen, A. Yasmeen, A. Cupo, J.L. Torres, J.P. Julien, J.H. Lee, T. van Montfort, S.W. de Taeye, et al. 2015. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog. 11:e1004767. http://dx.doi.org/10.1371/journal.ppat.1004767
13. de Taeye, S.W., G. Ozorowski, A. Torrents de la Peña, M. Guttman, J.P. Julien, T.L. van den Kerkhof, J.A. Burger, L.K. Pritchard, P. Pugach, A. Yasmeen, et al. 2015. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell. 163:1702-1715. http://dx.doi.org/10.1016/j.cell.2015.11.056
14. de Taeye, S.W., J.P. Moore, and R.W. Sanders. 2016. HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol. 37:221-232. http://dx.doi.org/10.1016/j.it.2016.01.007
15. Doria-Rose, N.A., C.A. Schramm, J. Gorman, P.L. Moore, J.N. Bhiman, B.J. DeKosky, M.J. Ernandes, I.S. Georgiev, H.J. Kim, M. Pancera, et al. NISC Comparative Sequencing Program. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 509:55-62. http://dx.doi.org/10.1038/nature13036
16. Dosenovic, P., L. von Boehmer, A. Escolano, J. Jardine, N.T. Freund, A.D. Gitlin, A.T. McGuire, D.W. Kulp, T. Oliveira, L. Scharf, et al. 2015. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell. 161:1505-1515. http://dx.doi.org/10.1016/j.cell.2015.06.003
17. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158
18. Escolano, A., J.M. Steichen, P. Dosenovic, D.W. Kulp, J. Golijanin, D. Sok, N.T. Freund, A.D. Gitlin, T. Oliveira, T. Araki, et al. 2016. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell. 166:1445-1458.e12. http://dx.doi.org/10.1016/j.cell.2016.07.030
19. Escolano, A., P. Dosenovic, and M.C. Nussenzweig. 2017. Progress toward active or passive HIV-1 vaccination. J. Exp. Med. 214:3-16. http://dx.doi.org/10.1084/jem.20161765
20. Euler, Z., M.J. van Gils, E.M. Bunnik, P. Phung, B. Schweighardt, T. Wrin, and H. Schuitemaker. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-1053. http://dx.doi.org/10.1086/651144
21. Euler, Z., E.M. Bunnik, J.A. Burger, B.D. Boeser-Nunnink, M.L. Grijsen, J.M. Prins, and H. Schuitemaker. 2011. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 85:7236-7245. http://dx.doi.org/10.1128/JVI.00196-11
22. Fera, D., A.G. Schmidt, B.F. Haynes, F. Gao, H.X. Liao, T.B. Kepler, and S.C. Harrison. 2014. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc. Natl. Acad. Sci. USA. 111:10275-10280. http://dx.doi.org/10.1073/pnas.1409954111
23. Garces, F., D. Sok, L. Kong, R. McBride, H.J. Kim, K.F. Saye-Francisco, J.P. Julien, Y. Hua, A. Cupo, J.P. Moore, et al. 2014. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell. 159:69-79. http://dx.doi.org/10.1016/j.cell.2014.09.009
24. Garces, F., J.H. Lee, N. de Val, A.T. de la Pena, L. Kong, C. Puchades, Y. Hua, R.L. Stanfield, D.R. Burton, J.P. Moore, et al. 2015. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity. 43:1053-1063. http://dx.doi.org/10.1016/j.immuni.2015.11.007
25. Gautam, R., Y. Nishimura, A. Pegu, M.C. Nason, F. Klein, A. Gazumyan, J. Golijanin, A. Buckler-White, R. Sadjadpour, K. Wang, et al. 2016. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 533:105-109. http://dx.doi.org/10.1038/nature17677
26. Gorman, J., C. Soto, M.M. Yang, T.M. Davenport, M. Guttman, R.T. Bailer, M. Chambers, G.Y. Chuang, B.J. DeKosky, N.A. Doria-Rose, et al. NISC Comparative Sequencing Program. 2016. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 23:81-90. http://dx.doi.org/10.1038/nsmb.3144
27. Gristick, H.B., L. von Boehmer, A.P. West Jr., M. Schamber, A. Gazumyan, J. Golijanin, M.S. Seaman, G. Fätkenheuer, F. Klein, M.C. Nussenzweig, and P.J. Bjorkman. 2016. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat. Struct. Mol. Biol. 23:906-915. http://dx.doi.org/10.1038/nsmb.3291
28. Haynes, B.F., G. Kelsoe, S.C. Harrison, and T.B. Kepler. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30:423-433. http://dx.doi.org/10.1038/nbt.2197
29. Hessell, A.J., P. Poignard, M. Hunter, L. Hangartner, D.M. Tehrani, W.K. Bleeker, P.W. Parren, P.A. Marx, and D.R. Burton. 2009. Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954. http://dx.doi.org/10.1038/nm.1974
30. Hraber, P., M.S. Seaman, R.T. Bailer, J.R. Mascola, D.C. Montefiori, and B.T. Korber. 2014. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 28:163-169. http://dx.doi.org/10.1097/QAD.0000000000000106
31. Jardine, J., J.P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P.S. Huang, S. MacPherson, M. Jones, et al. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science. 340:711-716. http://dx.doi.org/10.1126/science.1234150
32. Jardine, J.G., T. Ota, D. Sok, M. Pauthner, D.W. Kulp, O. Kalyuzhniy, P.D. Skog, T.C. Thinnes, D. Bhullar, B. Briney, et al. 2015. HIV-1 VAC CIN ES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science. 349:156-161. http://dx.doi.org/10.1126/science.aac5894
33. Jardine, J.G., D.W. Kulp, C. Havenar-Daughton, A. Sarkar, B. Briney, D. Sok, F. Sesterhenn, J. Ereño-Orbea, O. Kalyuzhniy, I. Deresa, et al. 2016. HIV-1 broadly neutralizing antibody precursor B cells revealed by germlinetargeting immunogen. Science. 351:1458-1463. http://dx.doi.org/10.1126/science.aad9195
34. Joyce, M.G., M. Kanekiyo, L. Xu, C. Biertümpfel, J.C. Boyington, S. Moquin, W. Shi, X. Wu, Y. Yang, Z.Y. Yang, et al. 2013. Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. J. Virol. 87:2294-2306. http://dx.doi.org/10.1128/JVI.02717-12
35. Julien, J.P., A. Cupo, D. Sok, R.L. Stanfield, D. Lyumkis, M.C. Deller, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, et al. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 342:1477-1483. http://dx.doi.org/10.1126/science.1245625
36. Kabat, E.A., T.T. Wu, H.M. Perry, K.S. Gottesmann, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest. Fifth edition. US Department of Health and Human Services, Washington, DC.
37. Karlsson, R., J.A. Mo, and R. Holmdahl. 1995. Binding of autoreactive mouse anti-type II collagen antibodies derived from the primary and the secondary immune response investigated with the biosensor technique. J. Immunol. Methods. 188:63-71. http://dx.doi.org/10.1016/0022-1759(95)00203-0
38. Klasse, P.J., C.C. LaBranche, T.J. Ketas, G. Ozorowski, A. Cupo, P. Pugach, R.P. Ringe, M. Golabek, M.J. van Gils, M. Guttman, et al. 2016. Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOS IP.664 trimers from clades A, B and C. PLoS Pathog. 12:e1005864. http://dx.doi.org/10.1371/journal.ppat.1005864
39. Klein, J.S., and P.J. Bjorkman. 2010. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6:e1000908. http://dx.doi.org/10.1371/journal.ppat.1000908
40. Klein, F., R. Diskin, J.F. Scheid, C. Gaebler, H. Mouquet, I.S. Georgiev, M. Pancera, T. Zhou, R.B. Incesu, B.Z. Fu, et al. 2013a. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 153:126-138. http://dx.doi.org/10.1016/j.cell.2013.03.018
41. Klein, F., H. Mouquet, P. Dosenovic, J.F. Scheid, L. Scharf, and M.C. Nussenzweig. 2013b. Antibodies in HIV-1 vaccine development and therapy. Science. 341:1199-1204. http://dx.doi.org/10.1126/science.1241144
42. Kong, L., B. Ju, Y. Chen, L. He, L. Ren, J. Liu, K. Hong, B. Su, Z. Wang, G. Ozorowski, et al. 2016. Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor. Immunity. 44:939-950. http://dx.doi.org/10.1016/j.immuni.2016.03.006
43. Labrijn, A.F., P. Poignard, A. Raja, M.B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C.C. Huang, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77:10557-10565. http://dx.doi.org/10.1128/JVI.77.19.10557-10565.2003
44. Li, Y., S. O'Dell, L.M. Walker, X. Wu, J. Guenaga, Y. Feng, S.D. Schmidt, K. McKee, M.K. Louder, J.E. Ledgerwood, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954-8967. http://dx.doi.org/10.1128/JVI.00754-11
45. Liao, H.X., R. Lynch, T. Zhou, F. Gao, S.M. Alam, S.D. Boyd, A.Z. Fire, K.M. Roskin, C.A. Schramm, Z. Zhang, et al. NISC Comparative Sequencing Program. 2013. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 496:469-476. http://dx.doi.org/10.1038/nature12053
46. Lynch, R.M., P. Wong, L. Tran, S. O'Dell, M.C. Nason, Y. Li, X. Wu, and J.R. Mascola. 2015. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89:4201-4213. http://dx.doi.org/10.1128/JVI.03608-14
47. Mascola, J.R., and B.F. Haynes. 2013. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254:225-244. http://dx.doi.org/10.1111/imr.12075
48. McGuire, A.T., S. Hoot, A.M. Dreyer, A. Lippy, A. Stuart, K.W. Cohen, J. Jardine, S. Menis, J.F. Scheid, A.P. West, et al. 2013. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210:655-663. http://dx.doi.org/10.1084/jem.20122824
49. McGuire, A.T., M.D. Gray, P. Dosenovic, A.D. Gitlin, N.T. Freund, J. Petersen, C. Correnti, W. Johnsen, R. Kegel, A.B. Stuart, et al. 2016. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun. 7:10618. http://dx.doi.org/10.1038/ncomms10618
50. McLellan, J.S., M. Pancera, C. Carrico, J. Gorman, J.P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 480:336-343. http://dx.doi.org/10.1038/nature10696
51. Medina-Ramírez, M., R.W. Sanders, and Q.J. Sattentau. 2017. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr. Opin. HIV AIDS. 12:241-249. http://dx.doi.org/10.1097/COH.0000000000000363
52. Mouquet, H., J.F. Scheid, M.J. Zoller, M. Krogsgaard, R.G. Ott, S. Shukair, M.N. Artyomov, J. Pietzsch, M. Connors, F. Pereyra, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 467:591-595. http://dx.doi.org/10.1038/nature09385
53. Neilson, J.R., G.C. John, J.K. Carr, P. Lewis, J.K. Kreiss, S. Jackson, R.W. Nduati, D. Mbori-Ngacha, D.D. Panteleeff, S. Bodrug, et al. 1999. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J. Virol. 73:4393-4403.
54. Ota, T., C. Doyle-Cooper, A.B. Cooper, M. Huber, E. Falkowska, K.J. Doores, L. Hangartner, K. Le, D. Sok, J. Jardine, et al. 2012. Anti-HIV B cell lines as candidate vaccine biosensors. J. Immunol. 189:4816-4824. http://dx.doi.org/10.4049/jimmunol.1202165
55. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326. http://dx.doi.org/10.1016/S0076-6879(97)76066-X
56. Pancera, M., J.S. McLellan, X. Wu, J. Zhu, A. Changela, S.D. Schmidt, Y. Yang, T. Zhou, S. Phogat, J.R. Mascola, and P.D. Kwong. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110. http://dx.doi.org/10.1128/JVI.00966-10
57. Pancera, M., T. Zhou, A. Druz, I.S. Georgiev, C. Soto, J. Gorman, J. Huang, P. Acharya, G.Y. Chuang, G. Ofek, et al. 2014. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 514:455-461. http://dx.doi.org/10.1038/nature13808
58. Peden, K., M. Emerman, and L. Montagnier. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 185:661-672. http://dx.doi.org/10.1016/0042-6822(91)90537-L
59. Pelanda, R., S. Schwers, E. Sonoda, R.M. Torres, D. Nemazee, and K. Rajewsky. 1997. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity. 7:765-775. http://dx.doi.org/10.1016/S1074-7613(00)80395-7
60. Pritchard, L.K., S. Vasiljevic, G. Ozorowski, G.E. Seabright, A. Cupo, R. Ringe, H.J. Kim, R.W. Sanders, K.J. Doores, D.R. Burton, et al. 2015. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Reports. 11:1604-1613. http://dx.doi.org/10.1016/j.celrep.2015.05.017
61. Pugach, P., G. Ozorowski, A. Cupo, R. Ringe, A. Yasmeen, N. de Val, R. Derking, H.J. Kim, J. Korzun, M. Golabek, et al. 2015. A native-like SOS IP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 89:3380-3395. http://dx.doi.org/10.1128/JVI.03473-14
62. Sanders, R.W., and J.P. Moore. 2017. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275:161-182. http://dx.doi.org/10.1111/imr.12481
63. Sanders, R.W., E. van Anken, A.A. Nabatov, I.M. Liscaljet, I. Bontjer, D. Eggink, M. Melchers, E. Busser, M.M. Dankers, F. Groot, et al. 2008. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology. 5:10. http://dx.doi.org/10.1186/1742-4690-5-10
64. Sanders, R.W., R. Derking, A. Cupo, J.P. Julien, A. Yasmeen, N. de Val, H.J. Kim, C. Blattner, A.T. de la Peña, J. Korzun, et al. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOS IP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9:e1003618. http://dx.doi.org/10.1371/journal.ppat.1003618
65. Sanders, R.W., M.J. van Gils, R. Derking, D. Sok, T.J. Ketas, J.A. Burger, G. Ozorowski, A. Cupo, C. Simonich, L. Goo, et al. 2015. HIV-1 VAC CIN ES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 349:aac4223. http://dx.doi.org/10.1126/science.aac4223
66. Saphire, E.O., R.L. Stanfield, M.D. Crispin, P.W. Parren, P.M. Rudd, R.A. Dwek, D.R. Burton, and I.A. Wilson. 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319:9-18. http://dx.doi.org/10.1016/S0022-2836(02)00244-9
67. Scharf, L., A.P. West Jr., H. Gao, T. Lee, J.F. Scheid, M.C. Nussenzweig, P.J. Bjorkman, and R. Diskin. 2013. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc. Natl. Acad. Sci. USA. 110:6049-6054. http://dx.doi.org/10.1073/pnas.1303682110
68. Scharf, L., A.P. West, S.A. Sievers, C. Chen, S. Jiang, H. Gao, M.D. Gray, A.T. McGuire, J.F. Scheid, M.C. Nussenzweig, et al. 2016. Structural basis for germline antibody recognition of HIV-1 immunogens. eLife. 5:e13783. http://dx.doi.org/10.7554/eLife.13783
69. Scheid, J.F., H. Mouquet, N. Feldhahn, M.S. Seaman, K. Velinzon, J. Pietzsch, R.G. Ott, R.M. Anthony, H. Zebroski, A. Hurley, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 458:636-640. http://dx.doi.org/10.1038/nature07930
70. Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333:1633-1637. http://dx.doi.org/10.1126/science.1207227
71. Shih, T.A., M. Roederer, and M.C. Nussenzweig. 2002. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3:399-406. http://dx.doi.org/10.1038/ni776
72. Shingai, M., O.K. Donau, R.J. Plishka, A. Buckler-White, J.R. Mascola, G.J. Nabel, M.C. Nason, D. Montefiori, B. Moldt, P. Poignard, et al. 2014. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211:2061-2074. http://dx.doi.org/10.1084/jem.20132494
73. Sliepen, K., M. Medina-Ramírez, A. Yasmeen, J.P. Moore, P.J. Klasse, and R.W. Sanders. 2015. Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology. 486:116-120. http://dx.doi.org/10.1016/j.virol.2015.08.002
74. Sok, D., M.J. van Gils, M. Pauthner, J.P. Julien, K.L. Saye-Francisco, J. Hsueh, B. Briney, J.H. Lee, K.M. Le, P.S. Lee, et al. 2014. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA. 111:17624-17629. http://dx.doi.org/10.1073/pnas.1415789111
75. Sok, D., B. Briney, J.G. Jardine, D.W. Kulp, S. Menis, M. Pauthner, A. Wood, E.C. Lee, K.M. Le, M. Jones, et al. 2016. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science. 353:1557-1560. http://dx.doi.org/10.1126/science.aah3945
76. Stamatatos, L., M. Pancera, and A.T. McGuire. 2017. Germline-targeting immunogens. Immunol. Rev. 275:203-216. http://dx.doi.org/10.1111/imr.12483
77. Steichen, J.M., D.W. Kulp, T. Tokatlian, A. Escolano, P. Dosenovic, R.L. Stanfield, L.E. McCoy, G. Ozorowski, X. Hu, O. Kalyuzhniy, et al. 2016. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity. 45:483-496. http://dx.doi.org/10.1016/j.immuni.2016.08.016
78. Tian, M., C. Cheng, X. Chen, H. Duan, H.L. Cheng, M. Dao, Z. Sheng, M. Kimble, L. Wang, S. Lin, et al. 2016. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell. 166:1471-1484.e18. http://dx.doi.org/10.1016/j.cell.2016.07.029
79. van den Kerkhof, T.L., K.A. Feenstra, Z. Euler, M.J. van Gils, L.W. Rijsdijk, B.D. Boeser-Nunnink, J. Heringa, H. Schuitemaker, and R.W. Sanders. 2013. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology. 10:102. http://dx.doi.org/10.1186/1742-4690-10-102
80. van Gils, M.J., and R.W. Sanders. 2013. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology. 435:46-56. http://dx.doi.org/10.1016/j.virol.2012.10.004
81. Verkoczy, L., F.W. Alt, and M. Tian. 2017. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol. Rev. 275:89-107. http://dx.doi.org/10.1111/imr.12505
82. Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al. Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285-289. http://dx.doi.org/10.1126/science.1178746
83. Walker, L.M., M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, et al. Protocol G Principal Investigators. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 477:466-470. http://dx.doi.org/10.1038/nature10373
84. Ward, A.B., and I.A. Wilson. 2017. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol. Rev. 275:21-32. http://dx.doi.org/10.1111/imr.12507
85. Weiss, M.S., and R. Hilgenfeld. 1997. On the use of the merging R factor as a quality indicator for X-ray data. J. Appl. Cryst. 30:203-205. http://dx.doi.org/10.1107/S0021889897003907
86. West, A.P. Jr., R. Diskin, M.C. Nussenzweig, and P.J. Bjorkman. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 109:E2083-E2090. http://dx.doi.org/10.1073/pnas.1208984109
87. Woods, A.S., H.Y. Wang, and S.N. Jackson. 2007. Sulfation, the up-andcoming post-translational modification: its role and mechanism in protein-protein interaction. J. Proteome Res. 6:1176-1182. http://dx.doi.org/10.1021/pr060529g
88. Wu, X., A.B. Parast, B.A. Richardson, R. Nduati, G. John-Stewart, D. Mbori-Ngacha, S.M. Rainwater, and J. Overbaugh. 2006. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80:835-844. http://dx.doi.org/10.1128/JVI.80.2.835-844.2006
89. Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N.S. Longo, M. Louder, K. McKee, et al. NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 333:1593-1602. http://dx.doi.org/10.1126/science.1207532
90. Xiao, X., W. Chen, Y. Feng, and D.S. Dimitrov. 2009a. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses. 1:802-817. http://dx.doi.org/10.3390/v1030802
91. Xiao, X., W. Chen, Y. Feng, Z. Zhu, P. Prabakaran, Y. Wang, M.Y. Zhang, N.S. Longo, and D.S. Dimitrov. 2009b. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390:404-409. http://dx.doi.org/10.1016/j.bbrc.2009.09.029
92. Yasmeen, A., R. Ringe, R. Derking, A. Cupo, J.P. Julien, D.R. Burton, A.B. Ward, I.A. Wilson, R.W. Sanders, J.P. Moore, and P.J. Klasse. 2014. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 11:41. http://dx.doi.org/10.1186/1742-4690-11-41
93. Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811-817. http://dx.doi.org/10.1126/science.1192819
94. Zhou, T., J. Zhu, X. Wu, S. Moquin, B. Zhang, P. Acharya, I.S. Georgiev, H.R. Altae-Tran, G.Y. Chuang, M.G. Joyce, et al. NISC Comparative Sequencing Program. 2013. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 39:245-258. http://dx.doi.org/10.1016/j.immuni.2013.04.012